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Fig. 1. Activation of HH andWnt pathways by HCV does not account for NS5A-
induced EMT. All experimental conditions were described in [3]. (A) Control and
HCV-infected PHH (see Fig. 3D in Akkari et al. [3]) were collected three weeks
after the infection and analysed by RT-qPCR to evaluate mRNA levels of
components of HH and Wnt pathways as well as Axin2, a Wnt signalling target
gene. Means ± SEM of three samples from one of three independent experiments
are shown. (B) Expression of HH andWnt pathways components and aWnt target
(Axin2) was analysed in BMEL-pMSCV and BMEL-NS5A cell lines. RT-qPCR
quantiﬁcation of mRNA was normalised to HPRT level and was arbitrarily set as 1
in control cells. Shh and Wnt5b mRNAs were below the level of detection in BMEL
cells. Means and values from two independent experiments quantiﬁed in
triplicate are shown. Statistical analysis was performed by unpaired Student’s t
test. ⁄p <0.05, ⁄⁄p <0.01.
Letters to the Editor
638 Journal of HepatologyConﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.
References
[1] Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, et al.
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses
from tumor suppression to epithelial–mesenchymal transition. PLoS One
2009;4:e4355.
[2] Wilson GK, Brimacombe CL, Rowe IA, Reynolds GM, Fletcher NF, Stamataki Z,
et al. A dual role for hypoxia inducible factor-1alpha in the hepatitis C virus
lifecycle and hepatoma migration. J Hepatol 2012;56:803–809.
[3] Akkari L, Gregoire D, Floc’h N, Moreau M, Hernandez C, Simonin Y, et al.
Hepatitis C viral protein NS5A induces EMT and participates in oncogenic
transformation of primary hepatocyte precursors. J Hepatol 2012;57:
1021–1028.
[4] Choi SS, Bradrick S, Qiang G, Mostafavi A, Chaturvedi G, Weinman SA, et al.
Up-regulation of Hedgehog pathway is associated with cellular permissive-
ness for hepatitis C virus replication. Hepatology 2011;54:1580–1590.
[5] Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-
mediated activation of phosphoinositide 3-kinase results in stabilization of
cellular beta-catenin and stimulation of beta-catenin-responsive transcrip-
tion. J Virol 2005;79:5006–5016.
[6] Milward A, Mankouri J, Harris M. Hepatitis C virus NS5A protein interacts
with beta-catenin and stimulates its transcriptional activity in a phosphoin-
ositide-3 kinase-dependent fashion. J Gen Virol 2010;91:373–381.
[7] Higgs MR, Lerat H, Pawlotsky JM. Hepatitis C virus-induced activation of beta-
catenin promotes c-Myc expression and a cascade of pro-carcinogenetic
events. Oncogene 2012, http://dx.doi.org/10.1038/onc.2012.484. [Epub ahead
of print].
[8] Fukutomi T, Zhou Y, Kawai S, Eguchi H, Wands JR, Li J. Hepatitis C virus core
protein stimulates hepatocyte growth: correlation with upregulation of wnt-
1 expression. Hepatology 2005;41:1096–1105.
[9] Liu J, Wang Z, Tang J, Tang R, Shan X, Zhang W, et al. Hepatitis C virus core
protein activates Wnt/beta-catenin signaling through multiple regulation
of upstream molecules in the SMMC-7721 cell line. Arch Virol 2011;156:
1013–1023.Damien Grégoire
Leila Akkari
Christophe Carenco
Urszula Hibner⇑
Institut de Génétique Moléculaire de Montpellier,
CNRS UMR5535, Montpellier, France⇑Corresponding author. Tel.: +33 434359656;
fax: +33 434359634
E-mail address: ula.hibner@igmm.cnrs.fractivated up to at least three weeks following HCV infection of
PHH (Fig. 1C). However, although we cannot exclude an early
transient activation of Wnt/b-catenin signalling in BMEL
expressing NS5A, we found no evidence either of increased
expression of components of this pathway or, more signiﬁcantly,
of sustained transcriptional activation of axin2 in BMEL-NS5A
cells undergoing EMT (Fig. 1D). Thus, our results suggest that
neither Hedgehog nor b-catenin signalling is required for NS5A-
mediated EMT. It remains an open question whether these path-
ways participate in EMT induction orchestrated by other HCV
proteins.Effect of albumin on survival in septic cirrhotic patients other
than spontaneous bacterial peritonitis. The question remains openTo the Editor:
We read the manuscript by Guevara et al. with interest [1]. The
authors evaluated the effect of albumin administration on the
3-month survival in cirrhotic patients hospitalized for infections
other than spontaneous bacterial peritonitis (SBP). After random-
ization, 54 and 56 patients received respectively antibiotics
alone, and both antibiotics plus intravenous albumin (1.5 g/kg
the ﬁrst day and 1 g/kg at day 3). The authors concluded that2albumin administration with antibiotics showed a potential sur-
vival beneﬁt in per-protocol analysis as compared with the con-
trol group, and that such a beneﬁcial effect was probably due
to the improvement in effective arterial blood volume reﬂected
by the improvement in renal function. However, we feel that
their conclusions may require closer examination.
First, this hopeful conclusion contrasts with the absence of a
3-month survival beneﬁt when the analysis was performed on013 vol. 58 j 634–640
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an intention-to-treat basis. The reason for the lack of signiﬁcance
in the intention-to-treat analysis could be related to the patients
withdrawn from the per-protocol analysis. Indeed, the overall
prognosis of these patients excluded from analysis was worse
(these patients had septic shock or unrecognized cardiomyopa-
thy) than those who remained in the analysis, and this may over-
estimate the albumin efﬁcacy. Thus, the per-protocol analysis
represents a ‘‘best-case scenario’’ to demonstrate the treatment
effect [2]. The patient selection could also explain this lack of sig-
niﬁcance since a progressive form of renal failure has been
observed only in sub-diaphragmatic infections [3]. Moreover,
the author’s assumption that albumin could improve the survival
rate by 30% (i.e., 3-month mortality rates of 55% in the control
group and 25% in the albumin group) was an over-optimistic pro-
jection that is not supported by the literature [4,5]. This also
explains the absence of any beneﬁcial effect of albumin in their
intention-to-treat analysis. Even in the sickest cirrhotic patients
with SBP, Sort et al. observed a 3-month mortality rate of 59%
in the group treated with antibiotics alone (control group), and
the difference in the survival rate between this control group
and the group of patients treated with both albumin and antibi-
otics was only 19% [4].
Second, the multivariate analysis performed to identify poten-
tial predictors of death included more variables than allowed by
the low number of events (18 deaths) observed. Consequently,
this may fail to provide valid estimates applicable to other sets
of patients. To avoid such overﬁtting, a predeﬁned ratio of candi-
date prognostic variables to the number of deaths should have
been set at 1:10 [6].
Third, the authors observed a signiﬁcant decrease in plasma
renin activity, aldosterone and norepinephrine concentration,
along with the stability of arterial pressure in the albumin group,
contrary to that observed in the control group. These data
probably support the improvement in renal function during the
ﬁrst week following albumin administration. However, we
should interpret this supposed improvement in renal function
with caution, because plasma renin activity, aldosterone and nor-
epinephrine concentration were measured in only 48 of the 97
patients enrolled in the analysis, which precludes the extrapola-
tion of measured values to the true mean values for the whole
population. From a clinical point of view, the incidence of renal
failure (serum creatinine >133 lmol/L) was low and not different
between the two groups (27.4% in the control group and 23.9% in
the albumin group). As stated honestly by Guevara et al., the low
incidence of renal insufﬁciency suggested that their study popu-
lation was not so sick. The absolute difference of only 2.2% in the
3-month survival rate between the two groups (80.4% in the con-
trol group vs. 82.6% in the albumin group) also precludes any
assumptions regarding the putative survival beneﬁt achieved by
improving renal function with albumin infusion.
Finally, this randomized study allows us to draw some conclu-
sions and assumptions for future trials. As reported previously,
albumin administration has demonstrated its beneﬁcial effects
on systemic hemodynamic and renal function in cirrhotic
patients with SBP, in terms of both an improvement in cardiac
function and a decrease in arterial vasodilatation [7]. This effect
may be unchanged in infections other than SBP. In Guevara’s
study [1], the beneﬁcial effect of albumin on survival is more con-
troversial, and the high number of patients (approximately 5000
per group) that would have been required to detect a 2.2% differ-
ence in survival rate, between those receiving albumin infusionJournal of Hepatology 20or not, will preclude further trials with such a ‘‘hard’’ end point.
Assessment of renal function is surely a valid surrogate, because
(1) creatinine level can be measured simply in the post-treatment
period, (2) renal insufﬁciency is strongly associated with death in
cirrhotic patients, and (3) renal function improves after albumin
treatment. As clearly stated by Guevara et al., the key issue to
highlight a beneﬁcial effect of albumin on survival would be to
investigate more fragile cirrhotic patients, particularly those with
ascites (but without SBP) associated or not with renal failure.
Large randomized studies are needed to conﬁrm the results of
Guevara’s study. We will soon report ﬁrst results from our ongo-
ing French ‘‘ALBCIRINF’’ study evaluating the effect of albumin on
renal function in severe cirrhotic patients, suffering from bacte-
rial infection other than SBP.
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